Work / Animation / HuLuc 63
PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.
Ozgur Sahin, PI, Nanomechanical Sensing, Rowland Institute at Harvard University
XVIVO has done an outstanding job for us. They engaged in our graphical design project with enthusiasm and took it to a level well beyond our imagination!